Translating world leading research in NMT into a pipeline of first-in-class ADC medicines for cancer
Myricx Bio (“Myricx”) is a UK biotech company focused on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer. NMT is an enzyme that adds a specific lipid modification to a number of protein targets key to cancer cell survival.
We are advancing a pipeline of ADCs based on our novel NMT inhibitor (NMTi) payload chemistry platform to address serious unmet needs in oncology. Our proprietary ADCs have demonstrated compelling preclinical efficacy and safety across multiple solid tumour associated antigens and specific cancer cell types.
Myricx has its office headquarters at the Gridiron Building in London’s fast growing biotech cluster around Kings Cross.
A private company, Myricx is backed by a syndicate of experienced investors including Brandon Capital Partners and Sofinnova Partners.